Q-omics provides the consensus-scored SBNO1 profile across patient tissues and cancer cell-line models. SBNO1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in UCS. Among the 18 cancer types available for tumor–normal comparison, SBNO1 is differentially expressed in 13, with the highest sampling consensus in KIRP. Additionally, SBNO1 protein abundance shows 23,649 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UCS, KIRP, and LSCC as cancer lineages where SBNO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SBNO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SBNO1 survival associations across molecular data types. SBNO1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (6) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SBNO1 RNA expression–survival associations across cancer types. High SBNO1 expression shows unfavorable associations in LIHC, KICH and UVM, but favorable associations in UCS, SCLC and KIRC. The UCS Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCS as the clearest survival context for SBNO1 RNA expression.
This table summarizes SBNO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for SBNO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SBNO1 shows lower tumor expression in THCA and higher tumor expression in KIRP, HNSC, LIHC, LUSC and STAD. The KIRP box plot shows higher SBNO1 RNA expression in tumor versus normal tissue (log2 FC = +1.287, t-test p < 0.001).
This table shows molecular features associated with SBNO1 in patient tissues and cancer cell lines. In patient samples, SBNO1 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SBNO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
